会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Anti-atherosclerotic diaryl compounds
    • 抗动脉粥样硬化二芳基化合物
    • US5395853A
    • 1995-03-07
    • US157685
    • 1993-11-24
    • William P. JacksonClifford J. HarrisRichard J. ArrowsmithJohn G. DannKevin J. O'ConnorRobert F. G. Booth
    • William P. JacksonClifford J. HarrisRichard J. ArrowsmithJohn G. DannKevin J. O'ConnorRobert F. G. Booth
    • C07C233/07C07C233/11C07C271/44C07C275/24C07C275/28C07C275/30C07C279/28C07C327/44A61K31/155A61K31/17C07C279/18
    • C07C233/07C07C233/11C07C271/44C07C275/24C07C275/28C07C275/30C07C279/28C07C327/44C07C2101/14
    • The present invention is concerned with compounds of formula (I) ##STR1## wherein m is 0 or 1;W is hydrogen, a C.sub.1-16 straight, branched, or cyclic alkyl group, or a C.sub.2-16 straight, branched, or cyclic alkenyl or alkynyl group, orPh(CH.sub.2).sub.n -- where Ph is phenyl and n is an integer of from 0 to 2, the phenyl group being optionally substituted by one or more atoms or groups independently selected from halogen, hydroxy, nitro, C.sub.1-4 alkoxy and C.sub.1-4 alkyl wherein one or more of the hydrogen atoms in said alkyl group is optionally replaced by halogen, orR.sup.1 NHCO-- where R.sup.1 is hydrogen or a C.sub.1-6 alkyl group, orR.sup.2 CONH-- where R.sup.2 is hydrogen or a C.sub.1-6 alkyl group; ##STR2## Y is --(CH.sub.2).sub.q, where q is an integer of from 1 to 3, or --CH.dbd.CH-- (E or Z);Z is a C.sub.1-6 alkyl group optionally substituted by one or more independently selected polar groups; andring A is optionally substituted by one or more atoms or groups independently selected from halogen, hydroxy, nitro, C.sub.1-4 alkoxy and C.sub.1-4 alkyl wherein one or more of the hydrogen atoms in said alkyl group is optionally replaced by halogen;provided said compound of formula (I) is not N-{2-[(4-methyl-phenyl)methyl]phenyl}acetamide or .alpha.-(p-tolyl)-o-cresol carbanilate; and salts, solvates and physiologically functional derivatives thereof, processes for the preparation of these compounds, pharmaceutical formulations containing them and their use in medicine.
    • 本发明涉及式(I)的化合物:其中m为0或1; W是氢,C1-16直链,支链或环状烷基或C2-16直链,支链或环状烯基或炔基或Ph(CH2)n-,其中Ph是苯基,n是整数 0至2,苯基任选被一个或多个独立地选自卤素,羟基,硝基,C 1-4烷氧基和C 1-4烷基的一个或多个原子或基团取代,其中所述烷基中的一个或多个氢原子是任选的 被卤素取代,或R1NHCO-,其中R1是氢或C1-6烷基,或R2CONH-,其中R2是氢或C1-6烷基; Y是 - (CH 2)q,其中q是1至3的整数,或-CH = CH-(E或Z); Z是任选被一个或多个独立选择的极性基团取代的C 1-6烷基; 并且环A任选被一个或多个独立地选自卤素,羟基,硝基,C 1-4烷氧基和C 1-4烷基的原子或基团取代,其中所述烷基中的一个或多个氢原子任选被卤素取代; 所述式(I)化合物不是N- {2 - [(4-甲基 - 苯基)甲基]苯基}乙酰胺或α-(对甲苯基) - 邻甲酚氨基苯甲酸酯; 及其盐,溶剂合物及其生理功能衍生物,制备这些化合物的方法,含有它们的药物制剂及其在药物中的用途。